Nine-Time Honoree: CMS Named “Honored Company” by Extel, and Ms. Chen Yanling Awarded “Best CFO”

Date:
2026-11-05
Category:
Company News

On November 5, the Asia Equities Awards Ceremony hosted by Extel (formerly known as “Institutional Investor”), an authoritative international financial magazine, was held in Hong Kong. China Medical System Holdings Limited (“CMS” or the “Group”) stood out among more than 1,000 participating companies and was recognized as an “Honored Company” of the “2026 Asia Executive Team” rankings in the biopharmaceuticals sector (Small & Mid Cap). Ms. Chen Yanling, the Group’s Executive Director, Chief Financial Officer and Vice President, ranked first overall for “Best CFO”  in the sector. This marks the Group’s ninth appearance in the rankings.

 

Extel is one of the professional capital market research and ranking institutions with broad influence in global capital markets. Its annual “Best Executive Team” rankings are an important benchmark for the international investment community to measure the management and investor relations performance of listed companies. This year’s survey gathered evaluations from 5,581 buy-side and sell-side professionals from 1,249 financial institutions. These honors reflect capital markets’ strong recognition of CMS’s corporate governance, investor relations and the professional capabilities of its management team.

 

Anchored by high standards of corporate governance, CMS regards investor relations as a vital link between the Group and the capital markets. It maintains an open and transparent dialogue with the capital market, using continuous, effective communication to bridge market perception and its management strategies. The Group’s management team actively promotes the deep integration of AI across the entire business operating and management chain, extending its application to investor communication to enhance the accessibility of information and interaction efficiency through intelligent tools. In April 2026, the Group launched “CMS AI Discovery”, an intelligent Q&A assistant developed based on large language model technology, on its official website. Based on publicly available information, the assistant provides investors and the public with timely, structured answers on the Group’s operating data, business layout, development strategy and R&D pipeline—marking a new stage in the Group’s AI-enabled external communications. Meanwhile, CMS remains committed to rewarding shareholders’ trust with sustained, stable and generous returns. Since its listing in 2010, the Group has distributed cumulative cash dividends of more than RMB10.4 billion.

 

Capital market recognition is not only rooted in the Group’s high-standard governance and communication, but also deeply grounded in its innovation-driven, high-quality growth momentum: The innovative pipeline is entering an accelerated harvest phase, with 9 approved innovative drugs and 4 innovative drugs (covering 5 indications) under NDA review, forming a multi-tiered portfolio in succession. Innovative and exclusive products have become the core growth engines. Its evidence-based academic promotion system, coupled with an omni-channel commercialization network spanning in-hospital and out-of-hospital markets and integrating online and offline channels, drives the efficient value realization of differentiated specialty pharmaceutical products across diverse settings. Meanwhile, overseas emerging market business anchored in Southeast Asia is advancing in depth, establishing a second growth curve in new regions supported by a localized operational infrastructure encompassing in-licensing, registration, manufacturing, and commercialization.

Looking forward, CMS will consolidate its foundations through sound governance, deepen mutual trust through professional dialogue and drive growth through high-quality decision-making. It will continue to demonstrate the value of innovation through patient benefits and reward the capital market’s long-term trust through sustainable value creation across market cycles.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.